Skip to main content
Top
Published in: Rheumatology International 4/2012

01-04-2012 | Original Article

Macrophage activation syndrome in children with systemic onset juvenile idiopathic arthritis: clinical experience from northwest India

Authors: Surjit Singh, Shanmuganathan Chandrakasan, Jasmina Ahluwalia, Deepti Suri, Amit Rawat, Nishath Ahmed, Reena Das, M. U. S. Sachdeva, Neelam Varma

Published in: Rheumatology International | Issue 4/2012

Login to get access

Abstract

The objective of this study is to describe the clinical and laboratory features of macrophage activation syndrome (MAS) in systemic onset juvenile idiopathic arthritis (SOJIA) at a tertiary care center in northwest India. Review of medical records of all children with SOJIA admitted during the period January 1995–December 2008 in Pediatric Allergy and Immunology Unit, Advanced Pediatrics Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, was done. Six patients (5 boys and 1 girl) with SOJIA and MAS were identified. Mean age at time of disease onset was 6.5 years. MAS was the presenting manifestation of SOJIA in 4 patients. Clinical manifestations included fever (6/6), clinical shock (6/6), encephalopathy (5/6), generalized lymphadenopathy (4/6), hepatosplenomegaly (3/6), jaundice and abdominal tenderness (3/6), cardiac involvement (3/6), and meningeal irritation (2/6). Laboratory findings at onset of MAS included decreasing total leukocyte and platelet counts, coagulopathy, elevated transaminases, hyponatremia, and lipid abnormalities. Hemophagocytosis was demonstrable in the bone marrow in 4 patients and in the lymph node in 1. For treatment, we used intravenous methylprednisolone (4/6), oral prednisolone (2/6), and intravenous immunoglobulin (2/6). Outcome was favorable in all patients except one who died of rapidly progressive disease. This paper describes the experience of JIA-related macrophage activation syndrome in a tertiary Indian center. We have shown that MAS can be the early presenting manifestation of evolving SOJIA. Early diagnosis and aggressive management can have a significant impact on the mortality associated with this syndrome. We stress on the role of glucocorticoids in the management of this condition and believe that glucocorticoids have a far more important role in the management of this condition than what has been previously reported.
Literature
1.
go back to reference Sawhney S, Woo P, Murray KJ (2001) Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child 85:421–426PubMedCrossRef Sawhney S, Woo P, Murray KJ (2001) Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child 85:421–426PubMedCrossRef
2.
go back to reference Stephan JL, Kone-Paut I, Galambrun C, Mouy R, Bader-Meunier B, Prieur AM (2001) Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients (oxford). Rheumatology (oxford) 40:1285–1292CrossRef Stephan JL, Kone-Paut I, Galambrun C, Mouy R, Bader-Meunier B, Prieur AM (2001) Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients (oxford). Rheumatology (oxford) 40:1285–1292CrossRef
3.
go back to reference Villanueva J, Lee S, Giannini EH, Graham TB, Passo MH, Filipovich A et al (2005) Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther 7:R30–R37PubMedCrossRef Villanueva J, Lee S, Giannini EH, Graham TB, Passo MH, Filipovich A et al (2005) Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther 7:R30–R37PubMedCrossRef
4.
go back to reference Grom AA, Villanueva J, Lee S, Goldmuntz EA, Passo MH, Filipovich A (2003) Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr 142:292–296PubMedCrossRef Grom AA, Villanueva J, Lee S, Goldmuntz EA, Passo MH, Filipovich A (2003) Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr 142:292–296PubMedCrossRef
5.
go back to reference Behrens EM, Beukelman T, Paessler M, Cron RQ (2007) Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 34:1133–1138PubMed Behrens EM, Beukelman T, Paessler M, Cron RQ (2007) Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 34:1133–1138PubMed
6.
go back to reference Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J et al (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31:390–392PubMed Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J et al (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31:390–392PubMed
7.
go back to reference Hadchouel M, Prieur AM, Griscelli C (1985) Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J Pediatr 106:561–566PubMedCrossRef Hadchouel M, Prieur AM, Griscelli C (1985) Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J Pediatr 106:561–566PubMedCrossRef
8.
go back to reference Stephan JL, Zeller J, Hubert P, Herbelin C, Dayer JM, Prieur AM (1993) Macrophage activation syndrome and rheumatic disease in childhood: a report of four new cases. Clin Exp Rheumatol 11:451–456PubMed Stephan JL, Zeller J, Hubert P, Herbelin C, Dayer JM, Prieur AM (1993) Macrophage activation syndrome and rheumatic disease in childhood: a report of four new cases. Clin Exp Rheumatol 11:451–456PubMed
9.
go back to reference Pringe A, Trail L, Ruperto N, Buoncompagni A, Loy A, Breda L et al (2007) Macrophage activation syndrome in juvenile systemic lupus erythematosus: an under-recognized complication? Lupus 16:587–592PubMedCrossRef Pringe A, Trail L, Ruperto N, Buoncompagni A, Loy A, Breda L et al (2007) Macrophage activation syndrome in juvenile systemic lupus erythematosus: an under-recognized complication? Lupus 16:587–592PubMedCrossRef
10.
go back to reference Avcin T, Tse SM, Schneider R, Ngan B, Silverman ED (2006) Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood. J Pediatr 148:683–686PubMedCrossRef Avcin T, Tse SM, Schneider R, Ngan B, Silverman ED (2006) Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood. J Pediatr 148:683–686PubMedCrossRef
11.
go back to reference Ravelli A, Magni-Manzoni S, Pistorio A, Besana C, Foti T, Ruperto N et al (2005) Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr 146:598–604PubMedCrossRef Ravelli A, Magni-Manzoni S, Pistorio A, Besana C, Foti T, Ruperto N et al (2005) Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr 146:598–604PubMedCrossRef
12.
go back to reference Silva CA, Silva CH, Robazzi TC, Lotito AP, Mendroni Junior A, Jacob CM et al (2004) Macrophage activation syndrome associated with systemic juvenile idiopathic arthritis. J Pediatr (Rio J) 80:517–522 Silva CA, Silva CH, Robazzi TC, Lotito AP, Mendroni Junior A, Jacob CM et al (2004) Macrophage activation syndrome associated with systemic juvenile idiopathic arthritis. J Pediatr (Rio J) 80:517–522
13.
go back to reference Pahwa R, Singh T, Khurana N (2004) Hemophagocytic syndrome in malaria and kala-azar. Indian J Pathol Microbiol 47:348–350PubMed Pahwa R, Singh T, Khurana N (2004) Hemophagocytic syndrome in malaria and kala-azar. Indian J Pathol Microbiol 47:348–350PubMed
14.
go back to reference Fame TM, Engelhard D, Riley HD Jr (1986) Hemophagocytosis accompanying typhoid fever. Pediatr Infect Dis 5:367–369PubMedCrossRef Fame TM, Engelhard D, Riley HD Jr (1986) Hemophagocytosis accompanying typhoid fever. Pediatr Infect Dis 5:367–369PubMedCrossRef
15.
go back to reference Dilber E, Erduran E, Kalyoncu M, Aynaci FM, Okten A, Ahmetoglu A (2002) Hemophagocytic syndrome as an initial presentation of miliary tuberculosis without pulmonary findings. Scand J Infect Dis 34:689–692PubMedCrossRef Dilber E, Erduran E, Kalyoncu M, Aynaci FM, Okten A, Ahmetoglu A (2002) Hemophagocytic syndrome as an initial presentation of miliary tuberculosis without pulmonary findings. Scand J Infect Dis 34:689–692PubMedCrossRef
16.
go back to reference Chen HH, Kuo HC, Wang L, Yu HR, Shen JM, Kwang KP et al (2007) Childhood macrophage activation syndrome differs from infection-associated hemophagocytosis syndrome in etiology and outcome in Taiwan. J Microbiol Immunol Infect 40:265–271PubMed Chen HH, Kuo HC, Wang L, Yu HR, Shen JM, Kwang KP et al (2007) Childhood macrophage activation syndrome differs from infection-associated hemophagocytosis syndrome in etiology and outcome in Taiwan. J Microbiol Immunol Infect 40:265–271PubMed
17.
go back to reference Ravelli A, Caria MC, Buratti S, Malattia C, Temporini F, Martini A (2001) Methotrexate as a possible trigger of macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol 28:865–867PubMed Ravelli A, Caria MC, Buratti S, Malattia C, Temporini F, Martini A (2001) Methotrexate as a possible trigger of macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol 28:865–867PubMed
18.
go back to reference Ramanan AV, Schneider R (2003) Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J Rheumatol 30:401–403PubMed Ramanan AV, Schneider R (2003) Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J Rheumatol 30:401–403PubMed
20.
go back to reference Bleesing J, Prada A, Siegel DM, Villanueva J, Olson J, Ilowite NT et al (2007) The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum 56:965–971PubMedCrossRef Bleesing J, Prada A, Siegel DM, Villanueva J, Olson J, Ilowite NT et al (2007) The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum 56:965–971PubMedCrossRef
21.
go back to reference Emmenegger U, Reimers A, Frey U, Fux C, Bihl F, Semela D et al (2002) Reactive macrophage activation syndrome: a simple screening strategy and its potential in early treatment initiation. Swiss Med Wkly 132:230–236PubMed Emmenegger U, Reimers A, Frey U, Fux C, Bihl F, Semela D et al (2002) Reactive macrophage activation syndrome: a simple screening strategy and its potential in early treatment initiation. Swiss Med Wkly 132:230–236PubMed
22.
go back to reference Ravelli A, Viola S, De Benedetti F, Magni-Manzoni S, Tzialla C, Martini A (2001) Dramatic efficacy of cyclosporine. A in macrophage activation syndrome. Clin Exp Rheumatol 19:108PubMed Ravelli A, Viola S, De Benedetti F, Magni-Manzoni S, Tzialla C, Martini A (2001) Dramatic efficacy of cyclosporine. A in macrophage activation syndrome. Clin Exp Rheumatol 19:108PubMed
23.
go back to reference Ogawa E, Otaguro S, Murata M, Kainuma M, Sawayama Y, Furusyo N et al (2008) Intravenous immunoglobulin therapy for severe arthritis associated with human parvovirus B19 infection. J Infect Chemother 14:377–382PubMedCrossRef Ogawa E, Otaguro S, Murata M, Kainuma M, Sawayama Y, Furusyo N et al (2008) Intravenous immunoglobulin therapy for severe arthritis associated with human parvovirus B19 infection. J Infect Chemother 14:377–382PubMedCrossRef
24.
go back to reference Tristano AG, Casanova-Escalona L, Torres A, Rodriguez MA (2003) Macrophage activation syndrome in a patient with systemic onset rheumatoid arthritis: rescue with intravenous immunoglobulin therapy. J Clin Rheumatol 9:253–258PubMedCrossRef Tristano AG, Casanova-Escalona L, Torres A, Rodriguez MA (2003) Macrophage activation syndrome in a patient with systemic onset rheumatoid arthritis: rescue with intravenous immunoglobulin therapy. J Clin Rheumatol 9:253–258PubMedCrossRef
25.
go back to reference Sakhalkar VS, Rao SP, Gottessman SR, Miller ST (2001) Hemophagocytosis and granulomas in the bone marrow of a child with Down syndrome. J Pediatr Hematol Oncol 23:623–625PubMedCrossRef Sakhalkar VS, Rao SP, Gottessman SR, Miller ST (2001) Hemophagocytosis and granulomas in the bone marrow of a child with Down syndrome. J Pediatr Hematol Oncol 23:623–625PubMedCrossRef
Metadata
Title
Macrophage activation syndrome in children with systemic onset juvenile idiopathic arthritis: clinical experience from northwest India
Authors
Surjit Singh
Shanmuganathan Chandrakasan
Jasmina Ahluwalia
Deepti Suri
Amit Rawat
Nishath Ahmed
Reena Das
M. U. S. Sachdeva
Neelam Varma
Publication date
01-04-2012
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 4/2012
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-010-1711-z

Other articles of this Issue 4/2012

Rheumatology International 4/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine